SSEA4 Recombinant Mouse mAb (Alexa Fluor? 647 Conjugate) (S-R541)

產(chǎn)品型號：S0B1847

更新時(shí)間：2025-07-02

廠商性質(zhì)：生產(chǎn)廠家

訪問量：68

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

葉酸受體α在癌癥治療策略中的多面性

IHC腫瘤標(biāo)志物 | 常見前列腺癌診斷

HA標(biāo)簽重組兔單抗具有增強(qiáng)蛋白定位的能力

產(chǎn)品介紹

The SSEA-4 （Stage-Specific Embryonic Antigen-4） is a significant glycolipid antigen belonging to the Globo series glycosphingolipids （such as Gb5 and SSEA-3）. Its structural characteristic is Neu5Gcα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-Cer. It is highly expressed during early embryonic development （e.g., in morula and blastocyst stages） and in pluripotent stem cells （such as human embryonic stem cells, hESCs, and induced pluripotent stem cells, iPSCs）, making it a widely used surface marker for pluripotency. Additionally, SSEA-4 is aberrantly expressed in various cancers （e.g., breast cancer, lung cancer, gliomas） and is associated with tumor progression, metastasis, and immune evasion, potentially through the regulation of cell adhesion or signaling pathways （e.g., EGFR/ERK）. Notably, since humans lack the enzyme to synthesize its sialic acid component （Neu5Gc）, SSEA-4 expression may rely on exogenous uptake or non-canonical biosynthetic pathways. This unique feature also presents a potential therapeutic target for cancer treatment.

上一個(gè)：S0B1846G4S Linker Recombinant Rabbit mAb (FITC Conjugate) (S-711-23)